Dystonia Therapeutics

Pipeline Assessment and Market Forecasts to 2018

Product Code GDA00795
Publication Date December 2011
Publisher GlobalData
Product Type Report
Pages 63
ISBN Number not applicable
Change currency
PDF £2,215.00 €2,667 $3,502 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Dystonia Therapeutics

Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Dystonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018'. The report is an essential source of information and analysis on the global Dystonia Therapeutics market. The report identifies the key trends shaping and driving the global Dystonia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Dystonia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Dystonia Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Dystonia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Dystonia Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Dystonia Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Dystonia Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Dystonia Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Dystonia Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Dystonia Therapeutics market landscape? - Identify, understand and capitalize.

Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Dystonia Therapeutics - Introduction
    • 2.1 Disease Overview
      • 2.1.1 Classification of Dystonia
    • 2.2 Epidemiology
      • 2.2.1 Quality of Life Parameters
    • 2.3 Pathophysiology
      • 2.3.1 Clinical Features
    • 2.4 Diagnosis
    • 2.5 Treatment and Management Options
    • 2.6 Referral Pathway
    • 2.7 GlobalData Pipeline Report Guidance
  • 3 Dystonia Therapeutics - Market Characterization
    • 3.1 Overview
    • 3.2 Dystonia Therapeutics Market Size (2005-2010) - Global
    • 3.3 Dystonia Therapeutics Market Forecast (2010-2018) - Global
    • 3.4 Dystonia Therapeutics Market Size (2005-2010) - The US
    • 3.5 Dystonia Therapeutics Market Forecast (2010-2018) - The US
    • 3.6 Dystonia Therapeutics Market Size (2005-2010) - France
    • 3.7 Dystonia Therapeutics Market Forecast (2010-2018) - France
    • 3.8 Dystonia Therapeutics Market Size (2005-2010) - Germany
    • 3.9 Dystonia Therapeutics Market Forecast (2010-2018) - Germany
    • 3.10 Dystonia Therapeutics Market Size (2005-2010) - Italy
    • 3.11 Dystonia Therapeutics Market Forecast (2010-2018) - Italy
    • 3.12 Dystonia Therapeutics Market Size (2005-2010) - Spain
    • 3.13 Dystonia Therapeutics Market Forecast (2010-2018) - Spain
    • 3.14 Dystonia Therapeutics Market Size (2005-2010) - The UK
    • 3.15 Dystonia Therapeutics Market Forecast (2010-2018) - The UK
    • 3.16 Dystonia Therapeutics Market Size (2005-2010) - Japan
    • 3.17 Dystonia Therapeutics Market Forecast (2010-2018) - Japan
    • 3.18 Drivers and Barriers for the Dystonia Therapeutics Market
      • 3.18.1 Drivers for the Dystonia Therapeutics Market
      • 3.18.2 Barriers for the Dystonia Therapeutics Market
    • 3.19 Opportunity and Unmet Need Analysis
    • 3.20 Key Takeaway
  • 4 Dystonia Therapeutics - Competitive Assessment
    • 4.1 Overview
    • 4.2 Strategic Competitor Assessment
    • 4.3 Product Profiles for the Major Marketed Products in the Dystonia Market
      • 4.3.1 Botox (onabotulinumtoxinA/Botulinum Toxin Type A)
      • 4.3.2 Xeomin (OncobotulinumtoxinA)
      • 4.3.3 Myobloc (RimabotulinumtoxinB)
      • 4.3.4 Dysport (abobotulinumtoxinA)
    • 4.4 Key Takeaway
  • 5 Dystonia Therapeutics - Pipeline Assessment
    • 5.1 Overview
    • 5.2 Strategic Pipeline Assessment
    • 5.3 Dystonia Therapeutics Pipeline - Pipeline by Phases of Development
      • 5.3.1 Dystonia Therapeutics - Phase III Pipeline
      • 5.3.2 Dystonia Therapeutics - Phase II Pipeline
      • 5.3.3 Dystonia Therapeutics - Phase I/Phase II Pipeline
      • 5.3.4 Dystonia Therapeutics - Phase I Pipeline
      • 5.3.5 Dystonia Market - Discovery and Pre-Clinical Pipeline
    • 5.4 Dystonia Therapeutics Market - Pipeline by Mechanism of Action
    • 5.5 Technology Trends Analytic Framework
    • 5.6 Molecule Profile for Drugs Under Phase III Development
      • 5.6.1 Dysport RU
    • 5.7 Key Takeaway
  • 6 Dystonia Therapeutics - Clinical Trials Mapping
    • 6.1 Clinical Trials by Region/Country (the US, EU5 and Japan)
    • 6.2 Clinical Trials by Phase
    • 6.3 Clinical Trials by Trial Status
    • 6.4 Prominent Sponsors
    • 6.5 Top Companies Participating in Dystonia Therapeutics Clinical Trials
  • 7 Strategic Assessment
    • 7.1 Key Events Impacting the Future Market
    • 7.2 Dystonia Therapeutics: Implications for Future Market Competition
  • 8 Dystonia Therapeutics - Future Players
    • 8.1 Introduction
    • 8.2 Company Profiles
      • 8.2.1 Ipsen S.A.
  • 9 Dystonia Therapeutics - Appendix
    • 9.1 Market Definitions
    • 9.2 Abbreviations
    • 9.3 Methodology
      • 9.3.1 Coverage
      • 9.3.2 Secondary Research
      • 9.3.3 Forecasting
      • 9.3.4 Primary Research
      • 9.3.5 Expert Panel Validation
    • 9.4 Contact Us
    • 9.5 Disclaimer
    • 9.6 Bibliography
    • 1.1 List of Tables
      • Table 1: Classification of Genetic Dystonia
      • Table 2: Physical Signs observed in Patients with Dystonia
      • Table 3: Drugs used for Dystonia
      • Table 4: Dystonia Therapeutics Market, Global, Revenue ($m), 2005-2010
      • Table 5: Dystonia Therapeutics Market, Global, Forecast ($m), 2010-2018
      • Table 6: Dystonia Therapeutics Market, The US, Revenue ($m), 2005-2010
      • Table 7: Dystonia Therapeutics Market, The US, Forecast ($m), 2010-2018
      • Table 8: Dystonia Therapeutics Market, France, Revenue ($m), 2005-2010
      • Table 9: Dystonia Therapeutics Market, France, Forecast ($m), 2010-2018
      • Table 10: Dystonia Therapeutics Market, Germany, Revenue ($m), 2005-2010
      • Table 11: Dystonia Therapeutics Market, Germany, Forecast ($m), 2010-2018
      • Table 12: Dystonia Therapeutics Market, Italy, Revenue ($m), 2005-2010
      • Table 13: Dystonia Therapeutics Market, Italy, Forecast ($m), 2010-2018
      • Table 14: Dystonia Therapeutics Market, Spain, Revenue ($m), 2005-2010
      • Table 15: Dystonia Therapeutics Market, Spain, Forecast ($m), 2010-2018
      • Table 16: Dystonia Therapeutics Market, The UK, Revenue ($m), 2005-2010
      • Table 17: Dystonia Therapeutics Market, The UK, Forecast ($m), 2010-2018
      • Table 18: Dystonia Therapeutics Market, Japan, Revenue ($m), 2005-2010
      • Table 19: Dystonia Therapeutics Market, Japan, Forecast ($m), 2010-2018
      • Table 20: Efficacy Outcomes of the Phase III Cervical Dystonia Study
      • Table 21: Number of Patients Treated per Muscle and Fraction of Total Dose Injected into Involved Muscles
      • Table 22: Dystonia Therapeutics, Phase III Pipeline, 2011
      • Table 23: Dystonia Therapeutics, Phase II Pipeline, 2011
      • Table 24: Dystonia Therapeutics, Phase I/Phase II Pipeline, 2011
      • Table 25: Dystonia Therapeutics, Phase I Pipeline, 2011
      • Table 26: Dystonia Therapeutics, Discovery and Pre-Clinical Pipeline, 2011
      • Table 27: Dystonia Therapeutics, Clinical Trials by Country, 2011
      • Table 28: Dystonia Therapeutics, Clinical Trials by Phase, 2011
      • Table 29: Dystonia Therapeutics, Clinical Trials by Status of Development, 2011
      • Table 30: Dystonia Therapeutics, Prominent Sponsors, 2011
      • Table 31: Dystonia Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
      • Table 32: Ipsen S.A. -Dystonia Pipeline Products, 2011
    • 1.2 List of Figures
      • Figure 1: Classification of Dystonia
      • Figure 2: Dystonia Diagnostic Algorithm
      • Figure 3: Referral Pathway for Dystonia
      • Figure 4: Dystonia Therapeutics Market, Global, Revenue ($m), 2005-2010
      • Figure 5: Dystonia Therapeutics Market, Global, Forecast ($m), 2010-2018
      • Figure 6: Dystonia Therapeutics Market, The US, Revenue ($m), 2005-2010
      • Figure 7: Dystonia Therapeutics Market, The US, Forecast ($m), 2010-2018
      • Figure 8: Dystonia Therapeutics Market, France, Revenue ($m), 2005-2010
      • Figure 9: Dystonia Therapeutics Market, France, Forecast ($m), 2010-2018
      • Figure 10: Dystonia Therapeutics Market, Germany, Revenue ($m), 2005-2010
      • Figure 11: Dystonia Therapeutics Market, Germany, Forecast ($m), 2010-2018
      • Figure 12: Dystonia Therapeutics Market, Italy, Revenue ($m), 2005-2010
      • Figure 13: Dystonia Therapeutics Market, Italy, Forecast ($m), 2010-2018
      • Figure 14: Dystonia Therapeutics Market, Spain, Revenue ($m), 2005-2010
      • Figure 15: Dystonia Therapeutics Market, Spain, Forecast ($m), 2010-2018
      • Figure 16: Dystonia Therapeutics Market, The UK, Revenue ($m), 2005-2010
      • Figure 17: Dystonia Therapeutics Market, The UK, Forecast ($m), 2010-2018
      • Figure 18: Dystonia Therapeutics Market, Japan, Revenue ($m), 2005-2010
      • Figure 19: Dystonia Therapeutics Market, Japan, Forecast ($m), 2010-2018
      • Figure 20: Opportunity and Unmet Need in the Dystonia Therapeutics Market, 2010
      • Figure 21: Dystonia Therapeutics, Strategic Competitor Assessment, 2010
      • Figure 22: Dystonia Therapeutics - Pipeline by Phase of Development, 2011
      • Figure 23: Dystonia Therapeutics, Pipeline by Mechanism of Action (%), 2011
      • Figure 24: Dystonia Therapeutics, Technology Trends Analytics Framework, 2011
      • Figure 25: Dystonia Therapeutics, Technology Trends Analytics Framework, Description, 2011
      • Figure 26: Dystonia Therapeutics, Clinical Trials by Country, 2011
      • Figure 27: Dystonia Therapeutics, Clinical Trials by Phase (%), 2011
      • Figure 28: Dystonia Therapeutics, Clinical Trials by Status of Development (%), 2011
      • Figure 29: Dystonia Therapeutics, Overall Sponsors (%), 2011
      • Figure 30: Dystonia Therapeutics, Prominent Sponsors (%), 2011
      • Figure 31: Dystonia Therapeutics Market, Drivers and Restraints, 2011
      • Figure 32: Implications for Future Market Competition in the Dystonia Market, 2011
      • Figure 33: Dystonia Therapeutics Market, Pipeline by Company, 2011
      • Figure 34: GlobalData Market Forecasting Model